Choose Your News
Loading...
Thumbnail
The video giant's latest viewing stats show that it remains in a league of its own. [Read More]
Thumbnail
The hypothetical....WMT... [Read More]
Thumbnail
It's hard to be too negative considering the speculative action today. [Read More]
From Brexit's first birthday to Diageo's Clooney purchase, here is what made headlines in Europe this week... [Read More]
Thumbnail
A sales miss fueled a big selloff on Friday. But much of the shortfall was due to one-time issues. [Read More]
Thumbnail
Jim Cramer discusses not discussing the 'market' and also suggests a Darth Vader-Amazon meeting....BMY... [Read More]
Thumbnail
In highlights from this week's trading diary and posts, Kass discusses Mae West and his latest trading activities....TLT... [Read More]
Jim Cramer is bullish on Ulta Beauty, Nutanix, Reynolds American, KeyCorp, and Broadcom....LUV... [Read More]
Thumbnail
Leo Denault, chairman and CEO of Entergy, tells Jim Cramer his company is investing in new power plants, more distribution lines and better technology....ETR... [Read More]
The British firm could attract attention from a slew of tech titans, despite the impending loss of Apple as a customer....AAPL... [Read More]
The DOJ and SEC are asking questions about how the company addressed the docmentary's effects in public documents....SEAS... [Read More]
Employment data say one thing, other economic signals contradict them, says Jim Cramer...SCHN... [Read More]
Jim Cramer says it seems the better Bed Bath & Beyond does online, the more it cannibalizes foot traffic in its stores....BBBY... [Read More]
Jim Cramer says if shares of Athena Health see a meaningful decline, it might be a buying opportunity....ATHN... [Read More]
Watch out for a negative impact as we head through the summer. [Read More]
With puts like SJM's they have to be good. [Read More]
There's been a delayed response to the good news for some companies. [Read More]
Here are the most important things that happened in the week ended June 23....BBRY... [Read More]
The Merck collab would count as Leap's first of planned studies with immunotherapies, but the collaboration is not Keytruda's first rodeo....LPTX... [Read More]
The trial for Martin Shkreli, the man alleged to have cheated investors and increasing a medication price by 5,000%, will begin Monday....RTRX... [Read More]
Loading...
The Street Popular Tags
Preview